{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"<p class=\"MsoNormal\" align=\"left\" style=\"margin:0cm 0cm .0001pt;line-height:13.4pt;\">Kontinuierliches vs. intermittierendes\n  Neuromonitoring zur Reduktion der passageren&#160;Recurrenspareserate in der Schilddr&#252;senchirurgie &#8211; eine prospektive, randomisierte,&#160;kontrollierte, multizentrische klinische Studie (CITY-Studie)</p><p class=\"MsoNormal\" align=\"left\" style=\"margin:0cm 0cm .0001pt;line-height:13.4pt;\">DRKS00033520</p>\n  \n \n<br />","eudractNumber":null,"id":9864,"indications":[{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-07-15T12:44:54+02:00","shortTitle":"CITY Trial","therapeutical":false,"therapyLines":[]},{"active":true,"description":"EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUK&#196;MIE (CLL): CLL-16 STUDIE DER DCLLSG","eudractNumber":"2020-004360-26","id":8660,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT05197192","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-25T14:28:21+02:00","shortTitle":"CLL16","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ \nsmall lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for \nadjustment of treatment duration to improve outcomes","eudractNumber":"2023-510294-34","id":11270,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-11T10:12:16+02:00","shortTitle":"CLL18 / MOIRAI-TRIAL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Beobachtungsstudie zum Verlauf der CML unter den neuen Erstlinientherapien","eudractNumber":null,"id":3460,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-01-01T11:09:29+01:00","shortTitle":"CML VI - Registerstudie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML)</div><div><br /></div><div><br /></div>","eudractNumber":null,"id":6082,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":null,"recruitmentStart":"2016-01-01T14:35:44+01:00","shortTitle":"CML-paed II Register","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;margin:12pt 0cm 6pt;\">COMPASS:\ndeCOMPressing stomA und zweistufige elektive Resektion vs. Notfall-Resektion\nbei Patienten mit linksseitigem obstruktivem Dickdarmkrebs</p><p class=\"MsoNormal\" align=\"center\" style=\"margin:12pt 0cm 6pt;text-align:left;\">DRKS00031827</p><p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;margin:12pt 0cm 6pt;\"><br /></p>","eudractNumber":null,"id":9179,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-01-31T13:39:30+01:00","shortTitle":"COMPASS","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Ivosidenib in combination with Azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany.","eudractNumber":null,"id":10267,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[],"nctNumber":"NCT06181734","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-09-13T09:23:35+02:00","shortTitle":"CONFIDHENCE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"COSS Register [COSSIRP] <br />= Klinisches Register f&#252;r Kinder, Jugendliche \nund Erwachsene mit Osteosarkomen und Knochentumoren. Das COSS-Register \nbeinhaltet keine Vorgaben an Diagnostik oder Therapie. [s. Homepage der <b>C</b>ooperative <b>O</b>steo<b>S</b>arkom <b>S</b>tudiengruppe, <b>COSS</b>]<br />","eudractNumber":null,"id":948,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2005-10-01T13:19:16+02:00","shortTitle":"COSS Register - COSSIRP","therapeutical":true,"therapyLines":[]},{"active":true,"description":"International CPT-SIOP-Registry<br />","eudractNumber":null,"id":1225,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2010-03-01T12:26:23+01:00","shortTitle":"CPT-SIOP Register","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Klinische Plattform zur Erforschung molekularer Ver&#228;nderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs","eudractNumber":null,"id":3383,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[],"nctNumber":"NCT02622581","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2015-08-16T08:23:05+02:00","shortTitle":"CRISP","therapeutical":false,"therapyLines":[]}]}